VSA-012

N/A

Report date: 2026/05/05 20:00:16
NME

Base Information

Drug NameVSA-012
Drug Alias NameVSA012VSA-012
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionComplement factor B modulators
TargetsComplement factor B
Therapy Area/IndicationsC3 glomerulopathyHemoglobinuria, ParoxysmalNephrosis +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesVisirna Therapeutics (Suzhou) Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesBisirna Therapeutics (Suzhou) Co LtdVisirna Therapeutics (Suzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsC3 glomerulopathyHemoglobinuria, ParoxysmalNephrosis +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A